Omnicom Health Group Acquires Archbow Consulting
Omnicom Health Group, the largest healthcare marketing and communications group in the world and part of Omnicom Group Inc. (NYSE: OMC), announced the acquisition of Archbow Consulting.
New Search
If you are not happy with the results below please do another search
Search
50 search results for:
Mayo Clinic Launches Joint Ventures to Create and Commercialize AI Diagnostic Tools
/in Algorithms, Artificial Intelligence, Business, Clinicians, Diagnostic Tools, Financing, Health Technology, Joint Ventures, Launches, Mayo Clinic, Medical Devices, Series AMayo Clinic launched two new tech venture companies designed to harness artificial intelligence (AI) and medical algorithms and create “software as medical devices” that clinicians can use to improve treatment across different diseases.
India’s coronavirus cases hit record as Mumbai prepares for new lockdown
/in Coronavirus Infections, COVID-19 cases, COVID-19 Lockdown Measures, Hospitalized COVID-19 Patients, India, Mumbai, ReutersIndia’s new coronavirus infections hit a record level on April 14 with Mumbai set to be locked down at midnight, but hundreds of thousands of pilgrims still thronged to a religious festival in the north of the country.
Healthcare collapse imminent, Brazil’s Sao Paulo warns, as Covid-19 cases surge
/in Brazil, Coronavirus Disease (COVID-19) Pandemic, COVID-19 cases, COVID-19 Deaths, Covid-19 Variant, Death Tolls, Healthcare, Newspapers, Outbreaks, Sao PauloBrazil’s richest and most populous state, Sao Paulo, warned its ability to care for seriously ill Covid-19 patients was on the verge of collapse as it ran perilously low on key drugs, according to a letter to the federal government seen by the Folha de Sao Paulo newspaper.
Elderly show similar antibody response to first dose of AstraZeneca, Pfizer Covid-19 shots: UK study
/in Antibodies, Antibody Response, AstraZeneca, BNT162b2 (Pfizer and BioNTech), Coronavirus Vaccines, COVID-19 shots, COVID-19 Vaccines, Elderly, Immune System, Pfizer, R&D, Researchers, SARS-CoV-2 virus, Scientists, T-Cells, United KingdomThe first study to directly compare immune reactions between Pfizer’s and AstraZeneca’s Covid-19 vaccines found strong and broadly similar antibody responses in over-80-year-olds after a first dose of either shot, scientists said on April 14.
SciNeuro and Eli Lilly Unite on Antibodies Deal
/in Antibodies, Business, China, Clinical Trials, Deals, Eli Lilly, Licensing, Neural tissue, Parkinson’s disease, R&DShanghai, China-based SciNeuro Pharmaceuticals and U.S.-based Eli Lilly inked an exclusive license deal to develop and commercialize alpha-synuclein targeted antibody treatments in Greater China
U.S. CDC to weigh rare clot risk with J&J’s Covid-19 vaccine as use paused
/in Advisory Panels, Blood Clots, CNN, COVID-19 Vaccines, Dr. Anthony Fauci (Director), FDA, Health Experts, Janssen, Janssen COVID-19 Vaccine (J&J), Joe Biden, Johnson & Johnson, MSNBC, U.S. Centers for Disease Control and PreventionA U.S. health advisory panel on April 14 is set to review six reported cases of rare blood clots in women who received Johnson & Johnson’s Covid-19 vaccine one day after federal regulators paused the use of the shot to assess the issue.
Havas Health & You Strengthens Capabilities in Innovation and Customer Experience
/in Appointments, Customer Experience, Data, Healthcare Communications Agencies, Healthcare Communications Networks, Innovation, Marketing & Advertising, People on the Move, PromotionsHavas Health & You announced their continued investment in Customer Experience and Innovation with several leadership changes.
AstraZeneca’s drug Tagrisso gets China nod for early lung cancer
/in Approvals, Blockbusters, China, China National Medical Products Administration (NMPA), Clinical Trials, Early Lung Cancer, EGFR Inhibitors, Epidermal Growth Factor Receptor (EGFR), R&D, TherapeuticsAstraZeneca Plc said on April 14 that China’s health regulator expanded the use of Tagrisso, the British drugmaker’s lung cancer treatment, in patients with a type of lung cancer when diagnosed at an early stage.
U.S. FDA Grants Accelerated Approval to Trodelvy for Treatment of Metastatic Urothelial Cancer
/in Accelerated Approval, Approvals, Boxed Warning, Clinical Data, FDA, Gilead, Metastatic Urothelial Cancer, New Indications, PD-1/PD-L1 inhibitors, Platinum-Based Chemotherapy, TherapeuticsThe U.S. Food and Drug Administration granted accelerated approval of Gilead Sciences Inc.’s Trodelvy (sacituzumab govitecan-hziy) for use in adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and either a programmed death receptor-1 or a programmed death-ligand 1 inhibitor.
